Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

(+)-Praeruptorin B is a pyranocoumarin that has been found in P. praeruptorum and has diverse biological activities.1,2,3,4 It inhibits RANKL-induced osteoclastogenesis of primary mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 10 µM and LPS-induced nitric oxide (NO) production in RAW 264.7 macrophages at 100 µM.2,1 (+)-Praeruptorin B inhibits platelet aggregation induced by platelet-activating factor (PAF) in isolated rabbit platelet-rich plasma (IC50 = 50 µM) and contractions of isolated guinea pig ileum induced by histamine (Item No. 22328) or leukotriene D4 (pD2s = 4.84 and 4.34, respectively).3 It decreases ovariectomy-induced bone loss in a mouse model of osteoporosis when administered at a dose of 10 mg/kg. (+)-Praeruptorin B (10 µmol/animal) reduces the number of tumors initiated by 7,12-dimethylbenz[a]anthracene (DMBA; Item No. 30383) and promoted by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) in a mouse two-stage model of skin carcinogenesis.4
WARNING This product is not for human or veterinary use.
1. Pyranocoumarins from root extracts of Peucedanum praeruptorum Dunn with multidrug resistance reversal and anti-
2. Praeruptorin B inhibits osteoclastogenesis by targeting GSTP1 and impacting on the S-
3. The antagonistic effects of khellactones on platelet-
4. Studies on the anti-